<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00365417</url>
  </required_header>
  <id_info>
    <org_study_id>NSABP FB-4</org_study_id>
    <nct_id>NCT00365417</nct_id>
  </id_info>
  <brief_title>Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer</brief_title>
  <official_title>A Phase II Clinical Trial of Bevacizumab Beginning Concurrently With a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy Followed by Postoperative Bevacizumab Alone for Women With Locally Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NSABP Foundation Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Drug Development Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NSABP Foundation Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bevacizumab is an angiogenesis inhibitor which means it works to stop blood vessel formation&#xD;
      in tumors. Without new blood vessels, the growth of a tumor is slowed. Chemotherapy drugs&#xD;
      kill cancer cells more directly. This study will evaluate:&#xD;
&#xD;
        -  How bevacizumab, given with chemotherapy before surgery, and then bevacizumab given&#xD;
           alone after surgery, will affect locally advanced breast tumors&#xD;
&#xD;
        -  Side effects from adding bevacizumab to chemotherapy&#xD;
&#xD;
        -  Whether adding bevacizumab to chemotherapy for breast cancer will affect the heart&#xD;
&#xD;
        -  If receiving bevacizumab will have any effect on how patients recover from surgery&#xD;
&#xD;
        -  Side effects of the combinations of drugs used in this study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Initial trials of neoadjuvant chemotherapy administered for locally advanced tumors,&#xD;
      including those in breast cancer, demonstrated therapy could induce sufficient tumor&#xD;
      regression to allow for the resection of otherwise unresectable tumors. Subsequent&#xD;
      demonstration of the equivalence of lumpectomy to mastectomy in patients with operable breast&#xD;
      cancer, stimulated interest in the concept of using preoperative chemotherapy to reduce&#xD;
      large, but operable, primary tumors to allow for lumpectomy in women who would otherwise&#xD;
      require a mastectomy. Given the data from previous studies, it is appropriate to continue&#xD;
      development of sequential doxorubicin/cyclophosphamide/docetaxel regimens to improve on&#xD;
      clinical and pathologic response rates. FB-4 is a Phase II, single arm study for women with&#xD;
      locally advanced human epidermal growth factor receptor 2 (HER2)-negative breast cancer&#xD;
      diagnosed by core needle biopsy. The primary aim of the study is to determine the pathologic&#xD;
      complete response rate in the breast following neoadjuvant chemotherapy combined with&#xD;
      bevacizumab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response (pCR) in the Breast</measure>
    <time_frame>Approximately 7 months</time_frame>
    <description>Measured by no histologic evidence of invasive tumor cells in the surgical breast specimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pCR in the Breast and Nodes</measure>
    <time_frame>Approximately 7 months</time_frame>
    <description>Measured by no histologic evidence of invasive tumor cells in the surgical breast specimen, axillary nodes, or sentinel nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response Rate (cRR) of the Sequential Regimen</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>Clinical tumor measurements were required before study entry &amp; before cycle 5 of chemotherapy (between AC &amp; TX). Final tumor measurements were obtained 4-5 weeks after the last dose of chemotherapy. Clinical tumor assessments by physical examination were recommended before each chemotherapy cycle. The criteria proposed by the Response Evaluation Criteria in Solid Tumors Committee(RECIST) were used to define clinical response status. CR was defined as the disappearance of all lesions with no evidence of PD. PR was defined as at least 30% decrease in the sum of the longest diameter of target lesions, using as reference the baseline sum longest diameter and/or the persistence of greater than or equal to 1 nontarget lesion without worsening of any other clinical manifestations of disease. PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, the appearance of new lesions, or unequivocal progression of existing lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reported Adverse Events</measure>
    <time_frame>Approximately 14 months</time_frame>
    <description>Number of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Events</measure>
    <time_frame>Assessments throughout; up to 18 months following study entry</time_frame>
    <description>Events: Congestive Heart Failure; Cardiac Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of patients free from disease progression. Progression is determined using international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee. At least a 20% increase in the sum of the longest diameter of the target lesions. Other manifestations of progressive disease would also be classified as disease progression, eg., appearance of one or more new lesions in the breast, regional lymph nodes or distant sites, unequivocal progression of existing non-target lesions, and appearance of inflammatory carcinoma on clinical exam.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of patients alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With at Least One Surgical Complications (Wound Dehiscence, Infection, Seroma, or Hematoma).</measure>
    <time_frame>Two (2) years</time_frame>
    <description>Number of patients with at least one surgical complications (wound dehiscence, infection, seroma, or hematoma)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Doxorubicin+Cyclophosphamide+Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>15 mg/kg IV every 21 days x 4 cycles, then after clinical response assessment, 15 mg/kg IV every 21 days x 2 cycles, then following surgery, 15 mg/kg every 21 days x 10 cycles</description>
    <arm_group_label>Doxorubicin+Cyclophosphamide+Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>60 mg/m^2 IV every 21 days x 4 cycles</description>
    <arm_group_label>Doxorubicin+Cyclophosphamide+Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>600 mg/m^2 IV every 21 days x 4 cycles</description>
    <arm_group_label>Doxorubicin+Cyclophosphamide+Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Following clinical response assessment, 650 mg/m^2 twice a day (orally), days 1-14 every 21 days x 4 cycles</description>
    <arm_group_label>Doxorubicin+Cyclophosphamide+Bevacizumab</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Following clinical response assessment, 75 mg/m^2 IV every 21 days x 4 cycles</description>
    <arm_group_label>Doxorubicin+Cyclophosphamide+Bevacizumab</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be female.&#xD;
&#xD;
          -  The patient must be greater than/equal to 18 years old&#xD;
&#xD;
          -  The diagnosis of invasive adenocarcinoma of the breast must have been made by core&#xD;
             needle biopsy or limited incisional biopsy.&#xD;
&#xD;
          -  Patients must have clinical Stage IIIA, IIIB, or IIIC disease (American Joint&#xD;
             Committee on Cancer [AJCC] staging criteria) with a primary breast tumor that is&#xD;
             greater than/equal to 2.0 cm measured by clinical exam, unless the patient has&#xD;
             inflammatory breast carcinoma, in which case measurable disease is not required.&#xD;
&#xD;
          -  Patients must have the ability to swallow oral medication.&#xD;
&#xD;
          -  The patient's Eastern Cooperative Oncology Group (ECOG) performance status must be 0&#xD;
             or 1.&#xD;
&#xD;
          -  At the time of study entry, blood counts must meet the following criteria:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) must be greater than/equal to 1200/mm3.&#xD;
&#xD;
               -  Platelet count must be greater than/equal to 100,000/mm^3.&#xD;
&#xD;
               -  Hemoglobin must be greater than/equal to 10 g/dL.&#xD;
&#xD;
          -  The following criteria for evidence of adequate hepatic function must be met:&#xD;
&#xD;
               -  total bilirubin must be less than/equal to upper limit of normal (ULN) for the&#xD;
                  lab unless the patient has a grade 1 bilirubin elevation (greater than ULN to 1.5&#xD;
                  x ULN) due to Gilbert's disease or similar syndrome involving slow conjugation of&#xD;
                  bilirubin; and&#xD;
&#xD;
               -  alkaline phosphatase must be less than 2.5 x ULN for the lab; and&#xD;
&#xD;
               -  aspartate aminotransferase (AST) must be less than/equal to 1.5 x ULN for the&#xD;
                  lab.&#xD;
&#xD;
               -  Alkaline phosphatase and AST may not both be greater than the ULN. For example,&#xD;
                  if the alkaline phosphatase is greater than the ULN but less than/equal to 2.5 x&#xD;
                  ULN, then the AST must be less than/equal to the ULN. If the AST is greater than&#xD;
                  the ULN but less than/equal to 1.5 x ULN, then the alkaline phosphatase must be&#xD;
                  less than/equal to ULN.&#xD;
&#xD;
          -  Patients with either skeletal pain or alkaline phosphatase that is greater than ULN&#xD;
             but less than/equal to 2.5 x ULN are eligible for inclusion in the study if a bone&#xD;
             scan or positron emission tomography (PET) scan does not demonstrate metastatic&#xD;
             disease. Patients with suspicious findings on bone scan or PET scan are eligible if&#xD;
             suspicious findings are confirmed as benign by x-ray, magnetic resonance imaging&#xD;
             (MRI), or biopsy.&#xD;
&#xD;
          -  Patients with AST or alkaline phosphatase greater than ULN are eligible for inclusion&#xD;
             in the study if liver imaging (computed tomography [CT], MRI, or PET scan) does not&#xD;
             demonstrate metastatic disease and adequate hepatic function.&#xD;
&#xD;
          -  The following criteria for evidence of adequate renal function must be met:&#xD;
&#xD;
               -  Serum creatinine less than/equal to ULN for the lab.&#xD;
&#xD;
               -  Calculated creatinine clearance must be greater than 50 mL/min.&#xD;
&#xD;
          -  Urine protein/creatinine (UPC) ratio must be less than 1.0.&#xD;
&#xD;
          -  Patients must have their left ventricular ejection fraction (LVEF) assessed by&#xD;
             multigated acquisition (MUGA) scan or echocardiogram within 3 months prior to study&#xD;
             entry. The LVEF must be greater than/equal to the lower limit of normal (LLN) for the&#xD;
             cardiac imaging facility performing the MUGA scan or echocardiogram. Note: If the&#xD;
             cardiac imaging facility cannot provide a LLN, use 50% as the LLN value.&#xD;
&#xD;
        Note: Since the pre-entry LVEF serves as the baseline for comparing subsequent LVEF&#xD;
        assessments to determine if bevacizumab therapy can be continued following doxorubicin and&#xD;
        cyclophosphamide (AC) and postoperatively, it is critical that this baseline study be an&#xD;
        accurate assessment of the patient's LVEF. If the baseline LVEF is greater than 65%, the&#xD;
        MUGA scan or echocardiogram must be repeated prior to study entry. The lower of the two&#xD;
        LVEF values should be used as the baseline LVEF.&#xD;
&#xD;
          -  Patients must have an electrocardiogram (EKG) within 3 months prior to study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumor determined to be strongly HER2-positive by immunohistochemistry (3+) or by&#xD;
             fluorescent in situ hybridization (positive for gene amplification).&#xD;
&#xD;
          -  Excisional biopsy for this primary tumor.&#xD;
&#xD;
          -  Synchronous bilateral invasive breast cancer.&#xD;
&#xD;
          -  Surgical axillary staging procedure prior to study entry (Exceptions: 1) fine needle&#xD;
             aspiration (FNA) of an axillary node is permitted for any patient, and 2) although not&#xD;
             recommended, a sentinel lymph node biopsy for patients with clinically negative&#xD;
             axillary nodes is permitted.)&#xD;
&#xD;
          -  History of any of the following cancers:&#xD;
&#xD;
               -  Ipsilateral breast cancer: invasive, ductal carcinoma in situ (DCIS) treated with&#xD;
                  any therapy other than excision&#xD;
&#xD;
               -  Contralateral breast cancer: invasive within the past 5 years (Patients with&#xD;
                  history of DCIS or synchronous DCIS are eligible)&#xD;
&#xD;
               -  History of non-breast malignancies within the 5 years prior to study entry.&#xD;
                  Patients with the following cancers are eligible if diagnosed and treated within&#xD;
                  the previous 5 years: carcinoma in situ of the cervix, carcinoma in situ of the&#xD;
                  colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.&#xD;
&#xD;
          -  Prior therapy with anthracyclines, taxanes, capecitabine, or bevacizumab for any&#xD;
             malignancy.&#xD;
&#xD;
          -  Treatment including radiation therapy, chemotherapy, biotherapy, and/or hormonal&#xD;
             therapy administered for the currently diagnosed breast cancer prior to study entry.&#xD;
             The only exception is hormonal therapy, which may have been given for up to a total of&#xD;
             28 days anytime after diagnosis and before study entry. In such a case, hormonal&#xD;
             therapy must stop at or before study entry and be re-started, if indicated, following&#xD;
             chemotherapy.&#xD;
&#xD;
          -  Any of the following cardiac conditions:&#xD;
&#xD;
               -  angina pectoris that requires the use of anti-anginal medication;&#xD;
&#xD;
               -  history of documented congestive heart failure;&#xD;
&#xD;
               -  serious cardiac arrhythmia requiring medication;&#xD;
&#xD;
               -  severe conduction abnormality;&#xD;
&#xD;
               -  valvular disease with documented cardiac function compromise; or&#xD;
&#xD;
               -  uncontrolled hypertension defined as blood pressure greater than 150/90 on&#xD;
                  antihypertensive therapy. (Patients with hypertension that is well controlled on&#xD;
                  medication are eligible.)&#xD;
&#xD;
          -  History of myocardial infarction documented by elevated cardiac enzymes or persistent&#xD;
             regional wall abnormalities on assessment of left ventricular (LV) function.&#xD;
&#xD;
          -  History of transient ischemic attack (TIA) or cerebrovascular accident (CVA).&#xD;
&#xD;
          -  History of other arterial thrombotic event within 12 months before study entry.&#xD;
&#xD;
          -  Symptomatic peripheral vascular disease.&#xD;
&#xD;
          -  Any significant bleeding within 6 months before study entry.&#xD;
&#xD;
          -  Serious or non-healing wound, skin ulcers, or bone fracture.&#xD;
&#xD;
          -  Gastroduodenal ulcer(s) determined by endoscopy to be active.&#xD;
&#xD;
          -  Invasive procedures defined as follows:&#xD;
&#xD;
               -  Major surgical procedure, open biopsy, or significant traumatic injury within 28&#xD;
                  days prior to planned start of study therapy. (Note: Placement of a vascular&#xD;
                  access device is not considered a major surgical procedure.)&#xD;
&#xD;
               -  Anticipation of need for major surgical procedures (other than the required&#xD;
                  breast surgery) during the course of the study.&#xD;
&#xD;
          -  Known bleeding diathesis or coagulopathy. (Patients on warfarin with an in-range&#xD;
             international normalized ratio [INR] [usually between 2 and 3] are eligible.)&#xD;
&#xD;
          -  Other nonmalignant systemic disease (cardiovascular, renal, hepatic, diabetes, etc.)&#xD;
             that would preclude the patient from receiving study treatment or would prevent&#xD;
             required follow-up.&#xD;
&#xD;
          -  Sensory/motor neuropathy greater than/equal to grade 2, as defined by the NCI's Common&#xD;
             Terminology Criteria for Adverse Events Version 3.0 (CTCAE v3.0).&#xD;
&#xD;
          -  Conditions that would prohibit administration of corticosteroids.&#xD;
&#xD;
          -  History of hypersensitivity reaction to drugs formulated with polysorbate 80.&#xD;
&#xD;
          -  Therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective&#xD;
             estrogen receptor modulator (SERM), either for osteoporosis or breast cancer&#xD;
             prevention. Patients are eligible only if these medications are discontinued prior to&#xD;
             study entry.&#xD;
&#xD;
          -  Any sex hormonal therapy, e.g., birth control pills, ovarian hormonal replacement&#xD;
             therapy, etc. These patients are eligible if this therapy is discontinued prior to&#xD;
             study entry. (Women of reproductive potential must agree to use an effective&#xD;
             non-hormonal method of contraception during study therapy and for at least 3 months&#xD;
             after completion of bevacizumab.)&#xD;
&#xD;
          -  Pregnancy or lactation at the time of study entry.&#xD;
&#xD;
          -  Use of any investigational agent within 4 weeks prior to enrollment in the study.&#xD;
&#xD;
          -  Psychiatric or addictive disorders or other conditions that, in the opinion of the&#xD;
             investigator, would preclude the patient from meeting the study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman Wolmark, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NSABP Foundation Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NSABP Foundation, Inc.</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 15, 2006</study_first_submitted>
  <study_first_submitted_qc>August 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2006</study_first_posted>
  <results_first_submitted>August 21, 2009</results_first_submitted>
  <results_first_submitted_qc>July 16, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 12, 2010</results_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSABP</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Locally advanced</keyword>
  <keyword>Neoadjuvant</keyword>
  <keyword>Locally advanced breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chemo Plus Bevacizumab</title>
          <description>Bevacizumab beginning concurrently with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy followed by postoperative bevacizumab alone for women with HER2 negative locally advanced breast cancer</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chemo Plus Bevacizumab</title>
          <description>Bevacizumab beginning concurrently with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy followed by postoperative bevacizumab alone for women with HER2 negative locally advanced breast cancer</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 to less than 50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 50 and 59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than 59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.8" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathologic Complete Response (pCR) in the Breast</title>
        <description>Measured by no histologic evidence of invasive tumor cells in the surgical breast specimen</description>
        <time_frame>Approximately 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neoadjuvant Study Treatment</title>
            <description>Doxorubicin, cyclophosphamide, and bevacizumab followed by docetaxel and capecitabine</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Complete Response (pCR) in the Breast</title>
          <description>Measured by no histologic evidence of invasive tumor cells in the surgical breast specimen</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pCR in the breast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No pCR in the breast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>pCR in the Breast and Nodes</title>
        <description>Measured by no histologic evidence of invasive tumor cells in the surgical breast specimen, axillary nodes, or sentinel nodes</description>
        <time_frame>Approximately 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neoadjuvant Study Treatment</title>
            <description>Doxorubicin, cyclophosphamide, and bevacizumab followed by docetaxel and capecitabine</description>
          </group>
        </group_list>
        <measure>
          <title>pCR in the Breast and Nodes</title>
          <description>Measured by no histologic evidence of invasive tumor cells in the surgical breast specimen, axillary nodes, or sentinel nodes</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pCR in the breast and nodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No pCR in the breast and nodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response Rate (cRR) of the Sequential Regimen</title>
        <description>Clinical tumor measurements were required before study entry &amp; before cycle 5 of chemotherapy (between AC &amp; TX). Final tumor measurements were obtained 4-5 weeks after the last dose of chemotherapy. Clinical tumor assessments by physical examination were recommended before each chemotherapy cycle. The criteria proposed by the Response Evaluation Criteria in Solid Tumors Committee(RECIST) were used to define clinical response status. CR was defined as the disappearance of all lesions with no evidence of PD. PR was defined as at least 30% decrease in the sum of the longest diameter of target lesions, using as reference the baseline sum longest diameter and/or the persistence of greater than or equal to 1 nontarget lesion without worsening of any other clinical manifestations of disease. PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, the appearance of new lesions, or unequivocal progression of existing lesions.</description>
        <time_frame>Approximately 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemo Plus Bevacizumab</title>
            <description>Bevacizumab beginning concurrently with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy followed by postoperative bevacizumab alone for women with HER2 negative locally advanced breast cancer</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response Rate (cRR) of the Sequential Regimen</title>
          <description>Clinical tumor measurements were required before study entry &amp; before cycle 5 of chemotherapy (between AC &amp; TX). Final tumor measurements were obtained 4-5 weeks after the last dose of chemotherapy. Clinical tumor assessments by physical examination were recommended before each chemotherapy cycle. The criteria proposed by the Response Evaluation Criteria in Solid Tumors Committee(RECIST) were used to define clinical response status. CR was defined as the disappearance of all lesions with no evidence of PD. PR was defined as at least 30% decrease in the sum of the longest diameter of target lesions, using as reference the baseline sum longest diameter and/or the persistence of greater than or equal to 1 nontarget lesion without worsening of any other clinical manifestations of disease. PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, the appearance of new lesions, or unequivocal progression of existing lesions.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.27" lower_limit="62.16" upper_limit="88.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reported Adverse Events</title>
        <description>Number of Adverse Events</description>
        <time_frame>Approximately 14 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neoadjuvant Study Treatment</title>
            <description>Doxorubicin, cyclophosphamide, and bevacizumab followed by docetaxel and capecitabine</description>
          </group>
        </group_list>
        <measure>
          <title>Reported Adverse Events</title>
          <description>Number of Adverse Events</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Events</title>
        <description>Events: Congestive Heart Failure; Cardiac Death</description>
        <time_frame>Assessments throughout; up to 18 months following study entry</time_frame>
        <population>Symptomatic cardiac toxicity was not observed in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Chemo Plus Bevacizumab</title>
            <description>Bevacizumab beginning concurrently with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy followed by postoperative bevacizumab alone for women with HER2 negative locally advanced breast cancer</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Events</title>
          <description>Events: Congestive Heart Failure; Cardiac Death</description>
          <population>Symptomatic cardiac toxicity was not observed in this study.</population>
          <units>cardiac events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Percentage of patients free from disease progression. Progression is determined using international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee. At least a 20% increase in the sum of the longest diameter of the target lesions. Other manifestations of progressive disease would also be classified as disease progression, eg., appearance of one or more new lesions in the breast, regional lymph nodes or distant sites, unequivocal progression of existing non-target lesions, and appearance of inflammatory carcinoma on clinical exam.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemo Plus Bevacizumab</title>
            <description>Bevacizumab beginning concurrently with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy followed by postoperative bevacizumab alone for women with HER2 negative locally advanced breast cancer</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Percentage of patients free from disease progression. Progression is determined using international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee. At least a 20% increase in the sum of the longest diameter of the target lesions. Other manifestations of progressive disease would also be classified as disease progression, eg., appearance of one or more new lesions in the breast, regional lymph nodes or distant sites, unequivocal progression of existing non-target lesions, and appearance of inflammatory carcinoma on clinical exam.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.69" lower_limit="42" upper_limit="70.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Percentage of patients alive.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemo Plus Bevacizumab</title>
            <description>Bevacizumab beginning concurrently with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy followed by postoperative bevacizumab alone for women with HER2 negative locally advanced breast cancer</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Percentage of patients alive.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.52" lower_limit="58.5" upper_limit="85.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With at Least One Surgical Complications (Wound Dehiscence, Infection, Seroma, or Hematoma).</title>
        <description>Number of patients with at least one surgical complications (wound dehiscence, infection, seroma, or hematoma)</description>
        <time_frame>Two (2) years</time_frame>
        <population>Of the 45 patients, 43 patients had surgery and therefore 43 patients in this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Chemo Plus Bevacizumab</title>
            <description>Bevacizumab beginning concurrently with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy followed by postoperative bevacizumab alone for women with HER2 negative locally advanced breast cancer</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With at Least One Surgical Complications (Wound Dehiscence, Infection, Seroma, or Hematoma).</title>
          <description>Number of patients with at least one surgical complications (wound dehiscence, infection, seroma, or hematoma)</description>
          <population>Of the 45 patients, 43 patients had surgery and therefore 43 patients in this outcome.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessments throughout up to 3 years, 3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chemo Plus Bevacizumab</title>
          <description>Bevacizumab beginning concurrently with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy followed by postoperative bevacizumab alone for women with HER2 negative locally advanced breast cancer</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Mucositis (clinical exam) - oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Mucositis (functional/symptomatic) - esophagus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Mucositis (functional/symptomatic) - oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pain - abdominal NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pain - back</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pain - musculoskeletal (hip)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Infection - catheter related</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Infection - lung (pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Infection - skin (cellulites)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Infection - ungual (nails)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Infection - urinary tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC - sinus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC - skin (cellulites)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC - upper airway NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC - urinary tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC - wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand-foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemaglobin</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic function</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmia - sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Mucositis (clinical exam) - oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Mucositis - oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Taste alteration</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Muscle weakness - whole body/generalized</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pain - abdominal NOS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pain - back</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pain - bone</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pain - chest/thorax</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pain - extremity-limb</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pain - head/headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pain - joint</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pain - muscle</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pain - oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pain - pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pain - throat/pharynx/larynx</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Infection (documented clincally) - upper airway NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Infection - bladder (urinary)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Infection - other (thrush)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC - bladder (urinary)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC - pharynx</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC - skin (cellulites)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Blood - other HCT</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Neuropathy - motor</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Neuropathy - sensory</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood Alteration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Mood alteration - anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Irregular menses</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dermatitis - radiation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hand-foot</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Diana Gosik</name_or_title>
      <organization>NSABP Foundation, Inc.</organization>
      <phone>412-339-5333</phone>
      <email>diana.gosik@nsabp.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

